WASHINGTON — The Trump administration’s newest drug pricing idea suggests change on a massive scale: it pitches a wholesale transformation of the way millions of Americans pay for drugs, one that could have a ripple effect into nearly every corner of the country’s health care system.

The proposal would effectively eliminate the rebates that drug makers pay insurance companies in Medicare and parts of Medicaid. Manufacturers pay these rebates to secure good placement on an insurer’s formulary, which makes it easier for patients to get those drugs and harder for them to get competitors’. The regulation, if finalized, would make using rebates a violation of federal bribery law. Instead, drug makers could offer discounts that are more directly passed onto consumers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Do you really think these good old boys at the PBM’s are gonna give up those billions they’ve been stealing all these years ? Ok so they’ll charge a fee to the manufacturer , but if the fed’s know that they’re gonna do this why don’t they prevent fees from being charged ? The problem still stems from
    what I’ve been saying all along…. Get rid of AWP as a cost basis !! AWP means nothing yet the PBM’s will still use that number. They should use WAC (wholesale aquisition cost) . This is the price the manufacturer sells their product to the wholesaler. Wholesalers work on a 2-3% margin . This is at least a more realistic pricing model. They really need to address other issues to level the playing field , like PBM’s owning mail order houses and being transparent as to what they pay pharmacies. If I was their client, I would insist on it !!!

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy